When 34-year-old Maria Rodriguez received her biopsy results at a Kaiser Permanente clinic in Oakland, the words "CIN 2"—moderate precancerous cervical cells—flashed on the screen, and her heart sank. But instead of rushing into surgery, her doctor suggested watchful waiting: regular follow-ups, not immediate excision. Three years later, Maria’s cells regressed on their own, and she avoided an invasive procedure that might have posed risks to future pregnancies. Her story reflects a growing medical consensus supported by a landmark study of 12,012 women across Northern California: for many, immediate treatment of CIN 2 isn’t just unnecessary—it may be avoidable without increasing cancer risk.
Cervical intraepithelial neoplasia grade 2, or CIN 2, sits in a gray zone. It’s not cancer, but it can sometimes progress to more severe disease. For decades, the standard response has been prompt excision—removing the abnormal tissue—often via a loop electrosurgical procedure. But because not all CIN 2 lesions advance, and because excisions carry risks like preterm birth and cervical stenosis, experts have questioned whether this approach does more harm than good for some patients. Now, research led by the National Cancer Institute, analyzing data from the Kaiser Permanente Northern California (KPNC) screening program between 2017 and 2023, offers compelling evidence that delaying treatment is not only safe but beneficial for many.
The study compared two groups: women who received excision within six months of diagnosis and those managed with continued surveillance. Over a three-year follow-up, the risk of developing invasive cervical cancer or CIN 3 or worse was nearly identical—no statistically significant difference. What did differ was the number of procedures: immediate treatment led to 5.7 times more excisions, many of which revealed no serious pathology upon removal. In contrast, delayed management allowed time for the body’s immune system to clear the HPV infection naturally, which occurred in over 60% of cases. By avoiding unnecessary surgeries, women also sidestepped potential complications, especially critical for those planning future pregnancies.
These findings, published in Annals of Internal Medicine, could reshape U.S. clinical guidelines, which currently lean toward immediate treatment for CIN 2. The data suggest a more nuanced approach—stratifying patients by risk factors like age, HPV subtype, and lesion size—could preserve health outcomes while reducing overtreatment. For clinics within the KPNC system, where structured follow-up is routine, this model is already proving effective. As one researcher noted, "We’re learning that sometimes, the most powerful medical intervention is patience."
With cervical cancer screening becoming more precise and follow-up systems more robust, the future of CIN 2 care may lie not in the scalpel, but in careful monitoring. For women like Maria, that means fewer procedures, less anxiety, and a renewed trust in the body’s ability to heal.